ASCO GU: Many kidney cancer patients left out of clinical trial discussions, survey reveals
Older kidney cancer patients also lack understanding of their remission and survival diagnosis.
By
Older kidney cancer patients also lack understanding of their remission and survival diagnosis.
ByRivus and Madrigal’s respective nonalcoholic steatohepatitis assets are also reviewed by Clinical Trials Arena.
ByCelularity in glioblastoma multiforme and Sino Biopharm in gastric cancer are also reviewed by Clinical Trials Arena.
ByThe EU’s Clinical Trials Regulation and information system aims to streamline applications and bolster transparency – but initial rollout could…
ByiOnctura’s and Blade’s respective assets in idiopathic pulmonary fibrosis are also reviewed by Clinical Trials Arena.
ByGlobalData’s Thematic Research ecosystem ranks companies on a scale of 1 to 5 based on their likelihood to tackle issues…
ByIn an exclusive, Clinical Trials Arena dives into Australia’s trial activity data to find out how the pandemic impacted the…
ByThe analysis is influenced by new biosimilars jobs, deals, patents, and mentions in company reports since January 2021.
ByThank you for subscribing to Clinical Trials Arena